Zelira Therapeutics : Appendix 4D & FY22 Interim Financial Report

About this update from Zelira Therapeutics Ltd.

For personal use only Appendix 4D 1. Company Details Name of Entity Zelira Therapeutics Limited ABN Half year ended ("current period") Half year ended ("previous period") 27 103 782 378 31 December 2021 31 December 2020 2. Results for announcement to the market AUD $ 2.1 Revenues from ordinary activities Up 700% to 727,699 2.2 Profit / (loss) from ordinary activities after tax attributable to members - 31 December 2020: loss of Down 56% to (5,613,420) ($3,594,626) 2.3 Net profit / (loss) for the period attributable to Down 56% to (5,613,420) members - 31 December 2020: loss of ($3,594,626) 2.4 Dividends Amount per security Franked amount per security Interim dividend declared N/A N/A 2.5 Record date for determining entitlements to the dividend N/A 2.6 Brief explanation of any of the figures in 2.1 to 2.4 above necessary to enable figures to be understood Commercialisation continued to ramp up during the period with sales momentum gaining for current products in market and new products being clinically tested and launched. Distribution agreements were entered into in both German and New Zealand and the Company successfully supported Levin Health's receipt of ethics approval for Phase 2A clinical trial for chronic pain. 3. Net tangible assets per security 31 December 2021 31 December 2020 Net tangible asset backing per ordinary security 0.006 0.008 4. Details of entities over which control has been gained or lost 4.1. Control gained over entities N/A use only 4.2. Control lost over entities N/A 5. Dividends Individual dividends per security Franked Amount per Amount security of Date dividend is amount per per foreign payable security at security source 30% tax dividend Interim dividend: Current year N/A N/A N/A N/A Previous year N/A N/A N/A N/A 6. Dividend reinvestment plans The dividend or distribution plans shown below are in operation. N/A The last date(s) for receipt of election notices for the dividend or distribution plans. N/A For personal 7. Details of associates and joint entities N/A 8. Foreign entities N/A 9. If the accounts are subject to audit dispute or qualification, details are described below. N/A Sign here: Date: 23 February 2022 Managing Director Print Name: Oludare Odumosu For personal use only 2021 HALF-YEAR FINANCIAL REPORT 31 DECEMBER 2021 Zelira Therapeutics Ltd ABN 27 103 782 378 For personal use only Zelira Therapeutics Ltd Half-Year Financial Report 31 December 2021 2 For personal use only Contents 4 Directors' Report 8 Auditor's Independence Declaration Condensed Consolidated 9 Statement of Comprehensive Income 10 Condensed Consolidated Statement of Financial Position 11 Condensed Consolidated Statement of Changes in Equity 12 13 24 25 27 Condensed Consolidated Statement of Cash Flows Notes to the Condensed Consolidated Financial Statements Directors' Declaration Independent Auditor's Review Report Corporate Directory All announcements and financial reports are available on our website www.zeliratx.com 3 Zelira Therapeutics Ltd Half-Year Financial Report 31 December 2021 This is an excerpt of the original content. To continue reading it, access the original document here .

View stock analysis, news, and events for Zelira Therapeutics Ltd.